AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01508312
Drug: brentuximab vedotin (SGN-35)
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
Trial: NCT00483717
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
Trial: NCT00561925
Drug: nevirapine IR
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg BID
Trial: NCT00561925
Drug: nevirapine XR
RxNorm normalized name: nevirapine Extended Release Oral Tablet
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg QD
Trial: NCT01662102
Drug: Zevalin
RxNorm normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zevalin administered intravenously.
Trial: NCT01662102
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered intravenously.
Trial: NCT01910363
Drug: A2NTX
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
Trial: NCT01910363
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
Trial: NCT00417417
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
Trial: NCT01508312
Drug: Brentuximab Vedotin (SGN-35)
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
Trial: NCT00078598
Drug: Rituximab or Iodine I 131 Tositumomab Therapy
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02989701
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
Trial: NCT00598910
Drug: Omacor
RxNorm normalized name: Omacor
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA
Trial: NCT00828009
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT00828009
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT01717300
Drug: Anacetrapib 100 mg
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet, oral, once daily for 24 weeks
Trial: NCT01717300
Drug: Placebo for anacetrapib 100 mg
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, orally, once daily for 24 weeks
Trial: NCT01717300
Drug: Anacetrapib 25 mg
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet, oral, once daily for 24 weeks
Trial: NCT01717300
Drug: Placebo for anacetrapib 25 mg
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, orally, once daily for 24 weeks
Trial: NCT01495403
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dosing
Trial: NCT02690948
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01072318
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5mg
Trial: NCT04004988
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00519753
Drug: Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
Trial: NCT01574729
Drug: Surgery combined with rAd-p53 gene therapy
RxNorm normalized name: ATP7A gene therapy
DrugBank: rsATP7A cDNA (DB17854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
Trial: NCT03426891
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
Trial: NCT03426891
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
Trial: NCT03426891
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
Trial: NCT02058303
Drug: Exparel Forearm block
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
Trial: NCT02058303
Drug: Bupivacaine supraclavicular block
RxNorm normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-30mL 0.5% bupivacaine
Trial: NCT01525069
Drug: Floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01525069
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01525069
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01525069
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00399906
Drug: BMS-582949
RxNorm normalized name: BMS-582949
DrugBank: BMS-582949 (DB12696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once daily, 12 weeks
Trial: NCT03236636
Drug: Icaritin
RxNorm normalized name: Icaritin
DrugBank: Icaritin (DB12672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
Trial: NCT04067817
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient who was received the treatment of phenylephrine
Trial: NCT00734539
Drug: fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
Trial: NCT04000633
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
Trial: NCT00649207
Drug: ABT-888
RxNorm normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsules
Trial: NCT04948372
Drug: Terlipressin treatment
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
Trial: NCT02366546
Drug: TBI-1301
RxNorm normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
Trial: NCT02366546
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
Trial: NCT00005068
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005068
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02592798
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept IV administered on Day 1, 15, 29 and then every 28 days
Trial: NCT00004808
Drug: fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00421928
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
Trial: NCT00421928
Drug: tapentadol (CG5503)
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
Trial: NCT01301157
Drug: Dovonex
RxNorm normalized name: Dovonex
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT00265993
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months.
Trial: NCT00320450
Drug: SB-681323
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03630315
Drug: OTX-TKI
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
Trial: NCT03630315
Drug: Anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care therapy used to block vascular endothelial growth factor
Trial: NCT01780740
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
Trial: NCT02608073
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
Trial: NCT01254617
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02608684
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab IV solution
Trial: NCT02608684
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine IV solution
Trial: NCT02608684
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin IV solution
Trial: NCT03886896
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion during surgery
Trial: NCT02785549
Drug: Amoxicillin/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 875mg/125mg/8 hours
Trial: NCT00791505
Drug: ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500 mg a day for 10 days
Trial: NCT00791505
Drug: trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2000 mg a day for 10 days
Trial: NCT01487798
Drug: biphasic human insulin 30
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Trial: NCT01487798
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Trial: NCT03297112
Drug: Perflutren Lipid Microspheres
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04400201
Drug: Remimazolam Tosilate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
Trial: NCT04400201
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
Trial: NCT00000197
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02230995
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose of metformin given as tablets
Trial: NCT02230995
Drug: empagliflozin/metformin
RxNorm normalized name: EMPAGLIFLOZIN/METFORMIN
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose empagliflozin/metformin given as fixed-dose combination tablet
Trial: NCT02230995
Drug: empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose of empagliflozin given as tablet
Trial: NCT00148317
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
Trial: NCT00148317
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
Trial: NCT00148317
Drug: cyclophoshamide
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
Trial: NCT00148317
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
Trial: NCT01678235
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01678235
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04273737
Drug: Amantadine Hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
Trial: NCT00335777
Drug: Migranal nasal spray at 1 hour
RxNorm normalized name: dihydroergotamine Metered Dose Nasal Spray [Migranal]
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
Trial: NCT04674423
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir Alafenamide treatment for 144 weeks
Trial: NCT02876549
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
Trial: NCT02876549
Drug: Primaquine 0.25 mg/kg/day
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg/day for 14 days
Trial: NCT02876549
Drug: Primaquine 0.75 mg/kg weekly
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg weekly for eight weeks
Trial: NCT02079246
Drug: Idalopirdine 60 mg
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, encapsulated tablets, orally
Trial: NCT02271204
Drug: Ibandronic acid
RxNorm normalized name: Ibandronic acid
DrugBank: Ibandronate (DB00710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed by physician
Trial: NCT01209416
Drug: Acipimox
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
Trial: NCT01209416
Drug: Ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
Trial: NCT04255238
Drug: Gemigliptin 50mg
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day